FRE logo

Firebrick Pharma Limited Stock Price

ASX:FRE Community·AU$7.7m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

FRE Share Price Performance

AU$0.027
-0.05 (-64.00%)
AU$0.027
-0.05 (-64.00%)
Price AU$0.027

FRE Community Narratives

There are no narratives available yet.

Trending Discussion

No trending discussion available.

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks
0 Rewards

Firebrick Pharma Limited Key Details

AU$410.7k

Revenue

AU$217.8k

Cost of Revenue

AU$192.9k

Gross Profit

AU$2.6m

Other Expenses

-AU$2.5m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.0086
46.96%
-596.85%
0%
View Full Analysis

About FRE

Founded
2012
Employees
n/a
CEO
Peter Molloy
WebsiteView website
firebrickpharma.com

Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.

Recent FRE News & Updates

Recent updates

No updates